We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tracon Pharmaceuticals Inc (TCON) USD0.001

Sell:$1.80 Buy:$1.97 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.80
Buy:$1.97
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.80
Buy:$1.97
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.

Contact details

Address:
4350 La Jolla Village Dr Ste 800
SAN DIEGO
92122-1247
United States
Telephone:
+1 (858) 5500780
Website:
www.traconpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TCON
ISIN:
US89237H2094
Market cap:
$33.53 million
Shares in issue:
20.08 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Charles Theuer
    President, Chief Executive Officer, Director
  • Scott Brown
    Chief Financial Officer, Chief Accounting Officer
  • Mark Wiggins
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.